Mortality risk among sulfonylureas: a systematic review and network meta-analysis (Q38281461)

1 September 2017

0 references

Mortality risk among sulfonylureas: a systematic review and network meta-analysis (English)

1 reference

1 September 2017

1 reference

1 reference

Scot H Simpson

1

1 reference

1 September 2017

Jayson Lee

2

1 reference

1 September 2017

Sabina Choi

3

1 reference

1 September 2017

Ben Vandermeer

4

1 reference

1 September 2017

Ahmed S Abdelmoneim

5

1 reference

1 September 2017

Travis R Featherstone

6

1 reference

1 September 2017

22 October 2014

1 reference

The Lancet: Diabetes & Endocrinology

1 September 2017

1 reference

1 September 2017

3

1 reference

1 September 2017

1

1 reference

1 September 2017

43-51

1 reference

Pharmacologic management of type 2 diabetes.

1 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Do sulfonylurea drugs increase the risk of cardiac events?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Preconditioning: a paradigm shift in the biology of myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Preconditioning and postconditioning: new strategies for cardioprotection.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Sulfonylureas and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Variations in tissue selectivity amongst insulin secretagogues: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Use patterns of antidiabetic regimens by patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Type 2 diabetes mellitus management in Canada: is it improving?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

National trends in treatment of type 2 diabetes mellitus, 1994-2007

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Blood Sugar Lowering Effects of Chlorpropamide and Tolbutamide: A Double Blind Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The Effects of Long-term Therapy with Oral Hypoglycemic Agents on the Oral Glucose Tolerance Test Dynamics in Male Chemical Diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Parachute approach to evidence based medicine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Evaluation of inconsistency in networks of interventions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and [...]

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970213-X

7 January 2021

10.1016/S2213-8587(14)70213-X

Identifiers

DOI

1 reference

1 September 2017

1 reference